Discovery of novel small molecule anti-HCV agents via the CypA inhibitory mechanism using o-acylation-directed lead optimization

Molecules

Volumn 20, Issue 6, 2015, Pages 10342-10359

  Yan, Wenzhong ^a   Qing, Jie ^b,c   Mei, Hanbing ^a   Mao, Fei ^a   Huang, Jin ^a   Zhu, Jin ^a   Jiang, Hualiang ^a,d   Liu, Lei ^b   Zhang, Linqi ^c   Li, Jian ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Tsinghua University   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anti HCV; CypA; O acylation; Small molecule inhibitor

Indexed keywords

ANTIVIRUS AGENT; CYCLOPHILIN A; MOLECULAR LIBRARY;

ACYLATION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HUMAN; IC50; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY; PRECLINICAL STUDY; SYNTHESIS; VIRUS REPLICATION;

ACYLATION; ANTIVIRAL AGENTS; CELL SURVIVAL; CYCLOPHILIN A; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84938267866     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200610342     Document Type: Article

References (34)

1. Te, H.S.; Jensen, D.M. Epidemiology of hepatitis B and C viruses: A global overview. Clin. Liver Dis. 2010, 14, 1-21.
2. Shepard, C.W.; Finelli, L.; Alter, M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5, 558-567.
3. World Health Organization (WHO). WHO Report on the Hepatitis C, 2012; WHO: Geneva, Switzerland, 2012.
4. Cui, H.; Qing, J.; Guo, Y.; Wang, Y.; Cui, L.; He, T.; Zhang, L.; Liu, L. Stapled peptide-based membrane fusion inhibitors of hepatitis C. Bioorg. Med. Chem. 2013, 21, 3547-3554.
5. Huang, S.; Qing, J.; Wang, S.; Wang, H.; Zhang, L.; Tang, Y. Design and synthesis of imidazo[1,2-α][1,8]-naphthyridine derivatives as anti-HCV agents via direct C-H arylation. Org. Biomol. Chem. 2014, 12, 2344-2348.
6. Lin, K.; Gallay, P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Res. 2013, 99, 68-77.
7. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F.X. Cyclophilin and peptidylprolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337, 476-478.
8. Galat, A. Peptidylprolyl cis/trans isomerases (immunophilins): Biological diversity-targets-functions. Curr. Top. Med. Chem. 2003, 3, 1315-1347.
9. Dornan, J.; Taylor, P.; Walkinshaw, M.D. Structures of immu-nophilins and their ligand complexes. Curr. Top. Med. Chem. 2003, 3, 1392-1409.
10. Zhou, D.J.; Mei, Q.; Li, J.T.; He, H.Y. Cyclophilin A and viral infections. Biochem. Biophys. Res. Commun. 2012, 424, 647-650.
11. Bienkowska-Haba, M.; Patel, H.D.; Sapp, M. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog. 2009, doi:10.1371/journal.ppat.1000524.
12. Handschumacher, R.E.; Harding, M.W.; Rice, J.; Drugge, R.J.; Speicher, D. W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226, 544-547.
13. Sedrani, R.; Kallen, J.; Cabrejas, L.M.M.; Papageorgiou, C.D.; Senia, F.; Rohrbach, S.; Wagner, D.; Thai, B., Eme, A.M.J.; France, J.; et al. Sanglifehrin-cyclophilin interaction: Degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data. J. Am. Chem. Soc. 2003, 125, 3849-3859.
14. Li, J.; Chen, J.; Gui, C.; Zhang, L.; Qin, Y.; Xu, Q.; Zhang, J.; Liu, H.; Shen, X.; Jiang, H. Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay. Bioorg. Med. Chem. 2006, 14, 2209-2224.
15. Li, J.; Chen, J.; Zhang, L.; Wang, F.; Gui, C.; Zhang, L.; Qin, Y.; Xu, Q.; Liu, H.; Nan, F.; et al. One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation. Bioorg. Med. Chem. 2006, 14, 5527-5534.
16. Li, J.; Zhang, J.; Chen, J.; Luo, X.; Zhu, W.; Shen, J.; Liu, H.; Shen, X.; Jiang, H. Strategy for discovering chemical inhibitors of human cyclophilin A: Focused library design, virtual screening, chemical synthesis and bioassay. J. Comb. Chem. 2006, 8, 326-337.
17. Guichou, J.F.; Viaud, J.; Mettling, C.; Subra, G.; Lin, Y.L.; Chavanieu, A. Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J. Med. Chem. 2006, 49, 900-910.
18. Watashi, K.; Hijikata, M.; Hosaka, M.; Yamaji, M.; Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38, 1282-1288.
19. Yang, F.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kenworthy, R.; Tang, H.L. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82, 5269-5278.
20. Chatterji, U.; Bobardt, M.; Selvarajah, S.; Yang, F.; Tang, H.L.; Sakamoto, N.; Vuagniaux, G.; Parkinson, T.; Gallay, P. The isomerase active site of Cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 2009, 284, 16998-17005.
21. Gaither, L.A.; Borawski, J.; Anderson, L.J.; Balabanis, K.A.; Devay, P.; Joberty, G.; Rau, C.; Schirle, M.; Bouwmeester, T.; Mickanin, C.; et al. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 2010, 397, 43-55.
22. Kaul, A.; Stauffer, S.; Berger, C.; Pertel, T.; Schmitt, J.; Kallis, S.; Lopez, M.Z.; Lohmann, V.; Luban, J.; Bartenschlager, R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009, doi:10.1371/journal.ppat.1000546.
23. Hanoulle, X.; Badillo, A.; Wieruszeski, J.M.; Verdegem, D.; Landrieu, I.; Bartenschlager, R.; Penin, F.; Lippens, G. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyI cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 2009, 284, 13589-13601.
24. Coelmont, L.; Hanoulle, X.; Chatterji, U.; Berger, C.; Snoeck, J.; Bobardt, M.; Lim, P.; Vliegen, I.; Paeshuyse, J.; Vuagniaux, G. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 2010, doi:10.1371/journal.pone.0013687.
25. Nag, A.; Robotham, J.M.; Tang, H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J. Virol. 2012, 86, 12616-12624.
26. Paeshuyse, J.; Kaul, A.; de Clercq, E.; Rosenwirth, B.; Dumont, J.M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The non-immunosuppressive cyclosporine DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43, 761-770.
27. Hopkins, S.; DiMassimo, B.; Rusnak, P.; Heuman, D.; Lalezari, J.; Sluder, A.; Scorneaux, B.; Mosier, S.; Kowalczyk, P.; Ribeill, Y.; et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 2012, 57, 47-54.
28. Ahmed-Belkacem, A.; Colliandre, L.; Ahnou, N.; Lerat, H.; Bessin, Y.; Barthe, P.; Bourget, W.; Douguet, D.; Guichou, J.F.; Pawlotsky, J.M. New cyclophilin inhibitors unrelated to cyclosporine potently inhibit HCV replication and revert HCV-induced mitochondrial dysfunction. In Hepatology; Wiley-Blackwell: Hoboken, NJ, USA, 2012.
29. Ni, S.; Yuan, Y.; Huang, J.; Mao, X.; Lv, M.; Zhu, J.; Shen, X.; Pei, J.; Lai, L.; Jiang, H.; Li, J. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J. Med. Chem. 2009, 52, 5295-5298.
30. Lam, A.M.; Espiritu, C.; Bansal, S.; Steuer, H.M.M.; Niu, C.; Zennou, V.; Keilman, M.; Zhu, Y.; Lan, S.; Otto, M.J.; et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 2012, 56, 3359-3368.
31. Prichard, M.N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14, 181-205.
32. Han, Q.; Xu, C.; Wu, C.; Zhu, W.; Yang, R.; Chen, X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 2009, 145, 63-73.
33. Wu, Y.; Liao, Q.; Yang, R.; Chen, X.; Chen, X. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res. 2011, 155, 406-414.
34. Kofron, J.L.; Kuzmic, P.; Kishore, V.; Colon-Bonilla, E.; Rich, D.H. Determination of kinetic constants for peptidyl prolyl cis-trans isomerasesby an improved spectrophotometric assay. Biochemistry 1991, 30, 6127-6134.